Comparative Pharmacology
Head-to-head clinical analysis: CYCLOPHOSPHAMIDE versus EMCYT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOPHOSPHAMIDE versus EMCYT.
CYCLOPHOSPHAMIDE vs EMCYT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to cell cycle nonspecific cytotoxicity. It requires hepatic metabolism by cytochrome P450 (CYP2B6, CYP3A4, CYP2C9) to form active metabolites, phosphoramide mustard and acrolein, which alkylate DNA and inhibit protein synthesis.
Estramustine is a combination of estradiol and nitrogen mustard. The estradiol moiety targets the drug to cells expressing estrogen receptors, while the nitrogen mustard alkylates DNA, inhibiting cell division primarily in prostate cancer cells.
400-600 mg/m2 IV every 2-4 weeks; or 50-100 mg/m2 orally daily for 7-14 days; or 1-2 g/m2 IV as a single dose every 3-4 weeks.
Estramustine phosphate sodium: 14 mg/kg/day orally in 3-4 divided doses, typically 140 mg four times daily. Administer on an empty stomach (1 hour before or 2 hours after meals).
None Documented
None Documented
Clinical Note
moderateCyclophosphamide + Verteporfin
"Cyclophosphamide may increase the cardiotoxic activities of Verteporfin."
Clinical Note
moderateCyclophosphamide + Digoxin
"Cyclophosphamide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCyclophosphamide + Digitoxin
"Cyclophosphamide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCyclophosphamide + Deslanoside
Terminal elimination half-life: 4-8 hours in adults with normal renal function; prolonged in renal impairment (up to 15 hours) and in children.
Terminal half-life of estramustine phosphate: ~20 hours; estromustine: ~14 hours; clinical context: supports daily dosing with accumulation over 5-7 days
Renal: approximately 30-60% of dose excreted unchanged in urine; biliary/fecal excretion is minimal (<5%).
Renal: primarily as estramustine phosphate, estromustine, and estradiol; <1% as unchanged drug; fecal: ~15%
Category D/X
Category C
Alkylating Agent
Alkylating Agent
"Cyclophosphamide may decrease the cardiotoxic activities of Deslanoside."